Talks are gaining ground that the anti-regulation mindset of president-elect Donald Trump may not spare even the FDA. The first 100 days action plan released by Trump in late October suggested that he may seek to cut the red tape at the FDA, ensuring expedited drug approval processes.
from RTT - Biotech http://ift.tt/2fGIcWD
via IFTTT
No comments:
Post a Comment